ScholarWorks@Gyeongsang National University

Browsing by Park, Keon UkAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 5 of 5

SCIESCOPUSKCI
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13open access

Yoo, Kwai Han; Lee, Su Jin; Cho, Jinhyun; Lee, Ki Hyeong; Park, Keon Uk; Kim, Ki Hwan; Cho, Eun Kyung; Choi, Yoon Hee; Kim, Hye Ryun; Kim, Hoon-Gu, et al.

ArticleIssue Date2019CitationCANCER RESEARCH AND TREATMENT, v.51, no.2, pp 718 - 726PublisherKOREAN CANCER ASSOCIATION
SCOPUSESCI
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18open access

Choi, Dae-Ho; Kim, Miso; Kim, Young Saing; Park, Keon Uk; Cho, Jang Ho; Kim, Hongsik; Lee, Ki Hyeong; Ahn, Heejoon; Kim, Il-Hwan; Lee, Kyung-Hee, et al.

ArticleIssue Date2024CitationJTO Clinical and Research Reports, v.5, no.12PublisherElsevier Inc.
SCIESCOPUSKCI
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

Lee, Ki Hyeong; Cho, Byoung Chul; Ahn, Myung-Ju; Lee, Yun-Gyoo; Lee, Youngjoo; Lee, Jong-Seok; Kim, Joo-Hang; Min, Young Joo; Lee, Gyeong-Won; Lee, Sung Sook, et al.

ArticleIssue Date2024CitationCancer Research and Treatment, v.56, no.1, pp 48 - 60Publisher대한암학회
SCIESCOPUS
Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma

Hong, Min Hee; Heo, Seong Gu; Lee, Yun-Gyoo; Kim, Hyo Song; Park, Keon Uk; Kim, Hoon-Gu; Ko, Yoon Ho; Chung, Ik-Joo; Min, Young Joo; Kim, Min Kyoung, et al.

ArticleIssue Date2020CitationCancer, v.126, no.20, pp 4521 - 4531PublisherJohn Wiley & Sons Inc.
SCIESCOPUS
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)open access

Sim, Sung Hoon; Kim, Jeong Eun; Kim, Min Hwan; Park, Yeon Hee; Kim, Jee Hyun; Suh, Koung Jin; Koh, Su-Jin; Park, Kyong Hwa; Kang, Myoung Joo; Ahn, Mi Sun, et al.

ArticleIssue Date2022CitationBreast, v.65, pp 172 - 178PublisherChurchill Livingstone
1

RSS_1.0 RSS_2.0 ATOM_1.0

Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532

COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어